50921-39-6

Basic information

• Product Name: 1-(4-CHLOROPHENYL)-1-CYCLOBUTANECARBOXYLIC ACID
• Synonyms: 1-(p-chlorophenyl)cyclobutanecarboxylic acid;1-(4-Chlorophenyl)cyclobutanecarboxylicacid;1-(4-CHLOROPHENYL)-1-CYCLOBUTANE- CARBOXYLIC ACID 94%;1-(4-Chlorophenyl)-1-cyclobutanecarboxylic acid,94%;1-(4-Chlorophenyl)-1-cyclobutanecarboxylic acid, 94% 5GR;1-(4-CHLOROPHENYL)-1-CYCLOBUTANECARBOXYLIC ACID;TIMTEC-BB SBB003443;Cyclobutanecarboxylic acid, 1-(4-chlorophenyl)-
• CAS NO: 50921-39-6
• Molecular Formula: C₁₁H₁₁ClO₂
• Molecular Weight: 210.66
• EINECS: 256-847-3
• Mol File: 50921-39-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 80-90 °C
• Boiling Point: 302.49°C (rough estimate)
• Flash Point: 165.73 °C
• Appearance: Light yellow to purple/Crystalline Powder
• Density: 1.1742 (rough estimate)
• Vapor Pressure: 1.64E-05mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• PKA: 4.26±0.20(Predicted)
• CAS DataBase Reference: 1-(4-CHLOROPHENYL)-1-CYCLOBUTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROPHENYL)-1-CYCLOBUTANECARBOXYLIC ACID(50921-39-6)
• EPA Substance Registry System: 1-(4-CHLOROPHENYL)-1-CYCLOBUTANECARBOXYLIC ACID(50921-39-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• Hazardous Substances Data: 50921-39-6(Hazardous Substances Data)

Usage

Chemical Properties

light yellow to purple crystalline powder

InChI:InChI=1/C11H11ClO2/c12-9-4-2-8(3-5-9)11(10(13)14)6-1-7-11/h2-5H,1,6-7H2,(H,13,14)/p-1

Upstream product

• 28049-61-8 1-(4-chlorophenyl)cyclobutanecarbonitrile 
• 534-22-5 2-methylfuran 
• 29480-09-9 1-(4-chlorophenyl)cyclobutan-1-ol 
• 140-53-4 p-chlorobenzyl cyanide 

Downstream Products

• 50921-41-0 1-(4-chlorophenyl)cyclobutylmethanol 
• 544476-22-4 1-[1-(4-chloro-phenyl)-cyclobutanecarbonyl]-piperidine-4-carboxylic acid ethyl ester 
• 405087-49-2 (2-chloromethyl-morpholine-4-yl)-[1-(4-chloro-phenyl)-cyclobutyl]-methanone 
• 405087-52-7 1-[1-(4-chloro-phenyl)-cyclobutanecarbonyl]-azetidine-3-carboxylic acid methyl ester 
• 405087-46-9 [1-(4-chlorophenyl)-cyclobutyl]-[3-(1-hydroxy-ethyl)-piperidin-1-yl]-methanone 
• 1032349-97-5 tert-butyl[1-(4-cyanophenyl)cyclobutyl]carbamate 
• 1032349-98-6 tert-butyl 1-(4-(2-phenylacetyl)phenyl)cyclobutylcarbamate 
• 1199556-10-9 1-[4-(1-methyl-8-phenyl-[1,2,4]triazolo[4,3-a]-1,5-naphthyridin-7-yl)phenyl]cyclobutanamine 
• 1199556-09-6 7-[4-(1-aminocyclobutyl)phenyl]-8-phenyl-[1,2,4]triazolo[4,3-a]-1,5-naphthylidin-1-amine 
• 1199555-32-2 7-[4-(1-aminocyclobutyl)-8-phenyl]-[1,2,4]triazole[4,3-a]-1,5-naphthyridin-1-ol 
• 1199556-61-0 tert-butyl {1-[4-(6-chloro-3-phenyl-1,5-naphthyridin-2-yl)phenyl]cyclobutyl}carbamate 
• 1199556-21-2 7-[4-(1-aminocyclobutyl)phenyl]-N-ethyl-8-phenyl-[1,2,4]triazolo[4,3-a]-1,5-naphthyridin-1-amine 
• 1199556-62-1 tert-butyl {1-[4-(6-hydrazino-3-phenyl-1,5-naphthyridin-2-yl)phenyl]cyclobutyl}carbamate 
• 1199556-63-2 tert-butyl {1-[4-(1-hydroxy-8-phenyl-[1,2,4]triazole[4,3-a]-1,5-naphthyridin-7-y)phenyl]cyclobutyl}carbamate 

Relevant articles and documents

Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclobutanes

We herein report the first example of iridium-catalyzed enantioselective C(sp3)–H borylation of cyclobutanes using benzoxazoline as the directing group. The combination of a chiral bidentate boryl ligand and an iridium precursor has found to effectively catalyze C(sp3)–H borylation to afford a variety of cyclobutylboronates with good to excellent enantioselectivities. We also demonstrate the synthetic utility of the current method by converting the stereogenic C—B bond to other functionalities.

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with 1a reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.

Therapeutic agents

Compounds of formula I STR1 in which R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R2 is H or C1-3 alkyl; R3 and/or R4 are H, formyl, C1-3 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl or R3 and R4 together with the nitrogen atom form a heterocyclic ring system; R5 and/or R6 are H, halo, CF3, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylthio or R5 and R6 together with the carbon atoms to which they are attached form a second benzene ring show therapeutic activity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.